Plain-English translation of NCT07495384 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new medication called combined with cisplatin (a standard chemotherapy drug) to see if it can treat ovarian cancer that has come back after previous treatment and has become resistant to platinum-based chemotherapy. Researchers want to measure how well the medication works and what side effects participants experience. About 40 people will participate in this study.
Ovarian cancer that returns and becomes resistant to standard platinum chemotherapy is very difficult to treat, and patients need new treatment options. This trial is designed to see if combining this medication with cisplatin might help people whose cancer has stopped responding to previous treatments.
You likely qualify if…
You likely don't qualify if…
You will receive combined with cisplatin chemotherapy as your treatment. You'll need to visit the hospital or clinic for treatment appointments and follow-up visits where your doctors will check how well the medication is working and monitor you for any side effects. The trial will assess your response to treatment and track your overall health throughout the study period.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China
Sponsor
The First Hospital of Jilin University
Enrollment target
~40 participants
Started
January 2025
Primary completion
November 2029
Age range
18 Years and older
Sex
Female only
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Zhentong Wei Medic
The First Hospital of Jilin University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.